File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A highly-sensitive anti-Mullerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer

TitleA highly-sensitive anti-Mullerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer
Authors
KeywordsAMH
Breast cancer
Chemotherapy
Ovarian function
Ovarian reserve
Issue Date2014
PublisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/ejca
Citation
European Journal of Cancer, 2014, v. 50 n. 14, p. 2367-2374 How to Cite?
AbstractAIM: Anti-Müllerian hormone (AMH) shows promise as a biomarker of the ovarian reserve but current assays are insufficiently sensitive to allow assessment of this post-chemotherapy in most women. We have assessed a new highly sensitive AMH assay (Ansh picoAMH) in the evaluation of ovarian activity in women with very low ovarian reserve after chemotherapy. METHODS: A prospective cohort and an independent validation cohort of premenopausal women with early breast cancer (eBC) were recruited at the time of diagnosis (combined n=98), and ovarian reserve markers 2-5 years later following chemotherapy were assessed in relation to menstrual activity. RESULTS: The picoAMH assay had a limit of detection of 7.5 pg/ml. AMH clearly distinguished women with ongoing menses from those with amenorrhoea at 2 years after diagnosis (mean 522 ± 169 versus 8.9 ± 1.3 pg/ml, P<0.0001) with high predictive value for continuing menses or amenorrhoea for the subsequent 3 years. AMH was detectable in more women than using a previous assay (P=0.004). Other markers of the ovarian reserve (follicle-stimulating hormone (FSH), inhibin B) were also of discriminatory value but to lesser extents. This finding was validated in a second, independent cohort of women treated for eBC. CONCLUSION: The 10-fold increased assay sensitivity showed very clear distinction between groups based on ovarian activity with excellent prediction of future menses or amenorrhoea. This will improve assessment of post-chemotherapy ovarian function in women and may aid treatment decisions. Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/201052
ISSN
2020 Impact Factor: 9.162
2015 SCImago Journal Rankings: 3.152
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChai, J-
dc.contributor.authorHowie, AF-
dc.contributor.authorCameron, DA-
dc.contributor.authorAnderson, RA-
dc.date.accessioned2014-08-21T07:10:56Z-
dc.date.available2014-08-21T07:10:56Z-
dc.date.issued2014-
dc.identifier.citationEuropean Journal of Cancer, 2014, v. 50 n. 14, p. 2367-2374-
dc.identifier.issn0959-8049-
dc.identifier.urihttp://hdl.handle.net/10722/201052-
dc.description.abstractAIM: Anti-Müllerian hormone (AMH) shows promise as a biomarker of the ovarian reserve but current assays are insufficiently sensitive to allow assessment of this post-chemotherapy in most women. We have assessed a new highly sensitive AMH assay (Ansh picoAMH) in the evaluation of ovarian activity in women with very low ovarian reserve after chemotherapy. METHODS: A prospective cohort and an independent validation cohort of premenopausal women with early breast cancer (eBC) were recruited at the time of diagnosis (combined n=98), and ovarian reserve markers 2-5 years later following chemotherapy were assessed in relation to menstrual activity. RESULTS: The picoAMH assay had a limit of detection of 7.5 pg/ml. AMH clearly distinguished women with ongoing menses from those with amenorrhoea at 2 years after diagnosis (mean 522 ± 169 versus 8.9 ± 1.3 pg/ml, P<0.0001) with high predictive value for continuing menses or amenorrhoea for the subsequent 3 years. AMH was detectable in more women than using a previous assay (P=0.004). Other markers of the ovarian reserve (follicle-stimulating hormone (FSH), inhibin B) were also of discriminatory value but to lesser extents. This finding was validated in a second, independent cohort of women treated for eBC. CONCLUSION: The 10-fold increased assay sensitivity showed very clear distinction between groups based on ovarian activity with excellent prediction of future menses or amenorrhoea. This will improve assessment of post-chemotherapy ovarian function in women and may aid treatment decisions. Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.-
dc.languageeng-
dc.publisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/ejca-
dc.relation.ispartofEuropean Journal of Cancer-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAMH-
dc.subjectBreast cancer-
dc.subjectChemotherapy-
dc.subjectOvarian function-
dc.subjectOvarian reserve-
dc.titleA highly-sensitive anti-Mullerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer-
dc.typeArticle-
dc.identifier.emailChai, J: jchai@hkucc.hku.hk-
dc.identifier.authorityChai, J=rp00241-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.ejca.2014.06.011-
dc.identifier.pmid25027307-
dc.identifier.pmcidPMC4166459-
dc.identifier.scopuseid_2-s2.0-85027947584-
dc.identifier.hkuros234827-
dc.identifier.hkuros253799-
dc.identifier.volume50-
dc.identifier.issue14-
dc.identifier.spage2367-
dc.identifier.epage2374-
dc.identifier.isiWOS:000341449200001-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0959-8049-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats